

1 **Potential gains in health-adjusted life expectancy by reducing burden of non-**
2 **communicable diseases: a population-based study**

3 Jun-Yan Xi¹, Wang-Jian Zhang¹, Zhuo Chen², Yan-Ting Zhang¹, Li-Chang Chen¹, Yu-Qin
4 Zhang¹, Xiao Lin^{1,*}, Yuan-Tao Hao^{1,3,4,5,*}.

5 1 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,
6 Guangzhou 510080, China;

7 2 Department of Health Policy and Management, College of Public Health, University of
8 Georgia, Athens, Georgia 30602, USA;

9 3 Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing
10 100191, China;

11 4 Sun Yat-sen Global Health Institute, Sun Yat-sen University, Guangzhou 510080, China;

12 5 Center for Health Information Research, Sun Yat-sen University, Guangzhou 510080, China.

13

14 *Correspondence to:

15 Yuan-Tao Hao, PhD

16 Peking University Center for Public Health and Epidemic Preparedness & Response,

17 Xueyuan Road, Haidian District, Beijing 100191, China;

18 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,

19 74th Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China.

20 Tel: +86-13610271412

21 Email: haoyt@bjmu.edu.cn

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Xiao Lin, PhD

24 Department of Medical Statistics, School of Public Health, Sun Yat-sen University,

25 74th Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China.

26 Tel: +86-15875327398

27 Email: linx87@mail.sysu.edu.cn

28

29 **Abstract**

30 **Background**

31 The United Nations Sustainable Development Goals (SDGs) target 3.4 aims to reduce
32 premature mortality attributable to non-communicable diseases (NCDs) by one-third of their
33 2015 levels by 2030. Although meeting this target leads to longevity, survivors may suffer from
34 long-term disability caused by NCDs. This paper quantifies the potential gains in health-
35 adjusted life expectancy for people aged 30-70 years ($HALE_{[30-70]}$) by examining the reductions
36 in disability in addition to premature mortality. Additionally, we also assessed the feasibility of
37 meeting the SDGs target 3.4.

38 **Methods**

39 We extracted data from the Global Burden of Disease Study 2019 for all NCDs and four major
40 NCDs (cancers, cardiovascular diseases, chronic respiratory diseases, and diabetes mellitus) in
41 188 countries from 1990 to 2019. Bayesian age-period-cohort models were used to predict
42 possible premature mortality in 2030. The life table was used to estimate the unconditional
43 probability of death and $HALE_{[30-70]}$. Estimates of the potential gains in $HALE_{[30-70]}$ were based
44 on three alternative future scenarios: a) eliminating all premature deaths and disability from a
45 specific cause, b) meeting SDGs target 3.4, and survivors' disability is eliminated, and c)
46 meeting SDGs target 3.4, but survivors remain disabled for the rest of their lives.

47 **Results**

48 In 2030, the unconditional probability of premature mortality for four major NCDs in most
49 countries remained at more than two-thirds of the 2015 baseline. In all scenarios, the high-
50 income group has the greatest potential gains in $HALE_{[30-70]}$, above the global average of

51 HALE_[30-70]. In scenario A, the potential gains in HALE_[30-70] of reducing premature mortality
52 for four major NCDs are significantly lower than those for all NCDs (range of difference for
53 all income groups: 2.88 - 3.27 years). In scenarios B and C, the potential gains of HALE_[30-70]
54 in reducing premature mortality for all NCDs and the four major NCDs are similar (scenario B:
55 0.14 - 0.22, scenario C: 0.05 - 0.19). In scenarios A and B, countries from the high-income
56 group have the greatest potential gains in HALE_[30-70] from cancer intervention, whilst countries
57 from the other income groups result in a greater possible HALE_[30-70] gains from cardiovascular
58 diseases control. In scenario C, countries from each income group have the largest potential
59 gains in HALE_[30-70] from diabetes reduction and chronic respiratory diseases prevention.

60 **Conclusions**

61 Achieving SDGs target 3.4 remains challenging for most countries. The elimination of
62 disability among the population who benefit from the target could lead to a sizable improvement
63 in HALE_[30-70]. Reducing premature death and disability at once and attaching equal importance
64 to each to in line with the WHO goal of "leaving no one behind".

65 **Keywords:** Bayesian age-period-cohort model; Global health; Health-adjusted life expectancy;
66 Non-communicable diseases; Sustainable Development Goals.

67 **Funding**

68 **Guangdong Basic and Applied Basic Research Foundation (2020A1515011294)**

69 Yuan-Tao Hao

70 **Guangdong Basic and Applied Basic Research Foundation (2020A1515110230)**

71 Xiao Lin

72 **Guangdong Basic and Applied Basic Research Foundation (2021A1515011765)**

73 Xiao Lin

74 **China Postdoctoral Science Foundation (grant 2021M693594)**

75 Xiao Lin

76 Additionally, Professor Yuan-Tao Hao gratefully acknowledges the support of K.C.Wong

77 Education Foundation.

78 The funders had no role in study design, data collection and interpretation, or the decision to

79 submit the work for publication.

80

81 **Introduction**

82 Reducing the burden of disease caused by non-communicable diseases (NCDs) is a critical
83 target of global public health efforts. According to the World Health Statistics 2021 released by
84 the World Health Organization (WHO), seven of the top ten causes of death in 2019 were NCDs,
85 and the proportion of mortalities attributable to NCDs increased from 60.8% in 2000 to 73.6%
86 in 2019^[1]. WHO focuses on four categories of NCDs, including cardiovascular diseases (CVD),
87 cancers, chronic respiratory diseases (CRD), and diabetes mellitus, which are the leading causes
88 of premature death from NCDs^[2]. Although the total mortality rate for the four NCDs is
89 declining, the total number of deaths associated with them is still increasing^[1]. In addition, the
90 impact of NCDs is particularly severe in low- and middle-income countries, where more than
91 three-quarters of global NCD deaths occur. The burden of NCDs in these countries is predicted
92 to continue increasing in the coming decades^[2]. Reducing premature mortality (the
93 unconditional probability of dying from the four major NCDs between the ages of 30 and 70)
94 by a third from 2015 levels by 2030 is on the United Nations (UN) agenda as Sustainable
95 Development Goals (SDGs) target 3.4^[3]. The NCD Countdown 2030 Report proposed more
96 comprehensive indicators and committed to leaving no one behind^[4,5]. Although members of
97 the UN General Assembly have stepped up their investment in health and begun to develop
98 framework legislation to strengthen national governance of NCDs, slow progress in NCDs
99 prevention and control may make it difficult to meet SDGs target 3.4^[6-8]. Trend analysis of
100 regional and country-level premature mortality attributable to NCDs from a global health
101 perspective provides an intuitive assessment of progress towards meeting SDGs target 3.4^[9,10].
102 Meeting the ambitious SDGs target 3.4 would have substantial effects on life expectancy

103 globally^[9]. However, neglected disability attributed to the four major NCDs may lead to
104 unhealthy longevity^[11,12]. Since 1990, there has been a marked shift towards a greater
105 proportion of burden due to years lived with disability (YLDs) from NCDs^[13]. Many excluded
106 disabilities are amenable to prevention and treatment, and some NCDs deaths can be postponed.
107 Therefore, the global agenda for promoting human prosperity should be expanded to
108 rehabilitate the disability of survivors who benefit from SDGs target 3.4. Health-adjusted life
109 expectancy can effectively estimate the healthy life span lost due to disability by decomposing
110 life expectancy into healthy and disability components^[14]. Assessing the potential of reducing
111 disability in survivors to extend health-adjusted life expectancy under the framework of SDGs
112 target 3.4 is key to highlighting the public health and socioeconomic significance of this
113 expanded target.

114 In this study, we grouped 188 countries according to the World Bank income classifications.
115 We fitted Bayesian age-period-cohort (BAPC) models based on historical premature mortality
116 trends from 1990 to 2019 and assessed the feasibility of meeting SDGs target 3.4 by 2030 based
117 on model projections. In addition, we considered three alternative future scenarios in 2030 to
118 quantify the potential gains in health-adjusted life expectancy between ages 30 and 70 years
119 ($HALE_{(30-70)}$) by reducing disability and premature mortality from non-communicable diseases.

120

121 **Methods**

122 **Data sources**

123 We obtained standard epidemiological measures from the Global Burden of Disease Study 2019
124 (GBD 2019) result for five cause clusters by country and year, including all-cause mortalities

125 or cause-specific mortalities (non-communicable diseases, neoplasms, cardiovascular diseases,
126 chronic respiratory diseases, and diabetes mellitus), demographics, years of life lost (YLLs)
127 and years lived with disability (YLDs). GBD 2019 is a multinational collaborative study that
128 estimates the burden of diseases in countries around the world and produces summary measures
129 of health. The study updates the datasets annually, thus consistent comparisons could be made
130 between sex, age, and across locations for 1990-2019. The data sources and methods are
131 described elsewhere^[13-15]. All datasets are available via the GBD 2019 website^[16].

132 Population projections for 2020-2030 were obtained from the World Population Prospects 2019.
133 This dataset provides the median, 80%, and 95% prediction intervals with quinquennial
134 population by country, sex, and five-year age groups (0-4, 5-9, 10-14, ..., 95-99, 100+). World
135 Population Prospects 2019 is probabilistic population projections produced and displayed by
136 the United Nations Population Division based on the Bayesian hierarchical models for the total
137 fertility rate and life expectancy at birth, with detailed methods reported previously^[17,18]. The
138 dataset is available online^[19].

139 In addition, we grouped selected countries based on the World Bank's classification, including
140 high-income countries, upper-middle-income countries, lower-middle-income countries, and
141 low-income countries^[20]. This study complies with the Guidelines for Accurate and Transparent
142 Health Estimates Reporting (GATHER) statement^[21].

143

144 **Analytical strategies**

145 The Bayesian APC models were fitted by NCDs cluster, gender, and country to predict possible
146 NCDs-attributable premature mortality in 2030, based on historical trends in premature

147 mortality from 1990 to 2019. The Bayesian APC models, which incorporates age, period, and
148 cohort heterogeneity, were developed with R software, using the BAPC package (R version
149 4.1.1)^[22]. BAPC package builds upon Integrated Nested Laplace Approximations (INLA) and
150 addresses complex convergence concerns introduced by Markov chain Monte Carlo
151 (MCMC)^[23]. The aim is to efficiently forecast future rates and counts within a fully Bayesian
152 inference setting. Specifically, we chose to use second-order random walk priors (RW2) for age,
153 period, and cohort effect, which penalizes deviations from a linear trend with better predictions.
154 The hyper prior for the precision (inverse variance) in the random walk priors is a Gamma
155 distribution with parameters a and b , and weak hyperparameters ($a=1$, $b=0.00005$) were set to
156 smooth the estimation^[24]. The dataset used for age-standardization was obtained from GBD
157 2019 global population estimates.

158 We estimated the potential gains in $HALE_{[30-70]}$ by applying cause-deleted life table methods to
159 cause-specific baseline premature mortality reported in 2015, using methods developed by
160 Sullivan^[14,25,26]. The key to estimating the potential gain in $HALE_{[30-70]}$ from a specific cause is
161 to calculate the cause-deleted death probability and cause-deleted disability prevalence, as
162 described in previous studies^[27,28], which is calculated assuming independence among causes
163 of death and disability. We considered three alternative future scenarios of premature mortality
164 reduction from what was observed in the baseline year 2015 as in the following.

165 a) Eliminating all premature deaths and disability from a specific cause to assess the maximum
166 potential to increase $HALE_{[30-70]}$, which reflects all health burdens of the specific cause.

167
$$CEHALE_{[30-70]} = \frac{1}{l_j} \left[\sum_{t=x}^w L_j \times \{1 - (YLD_i - YLD_j)\} \right]$$

168 b) Based on the expanded target, the unconditional probability of premature death from a

169 specific cause is reduced by one-third, and survivors' disability is eliminated, which reflects the
170 potential to increase $HALE_{[30-70]}$.

$$171 \quad CEHALE_{[30-70]} = \frac{1}{l_j} \left[\sum_{i=x}^{\omega} L_j \times \{1 - YLD_i\} \right]$$

172 c) Based on SDGs target 3.4, the unconditional probability of premature death from a specific
173 cause is reduced by one-third, but survivors are disabled for the rest of their lives, which reflects
174 the healthy years of life lost to disability due to the specific cause and is used as a reference.

$$175 \quad CEHALE_{[30-70]} = \frac{1}{l_j} \left[\sum_{i=x}^{\omega} L_j \times \left\{ 1 - \left(YLD_i + \frac{1}{3} \times YLL_j \right) \right\} \right]$$

176 Where l_j is the number of persons surviving to the exact age x_i after eliminating or reducing
177 by a third number of deaths attributed to the cause j , L_j is the number of person-years lived in
178 the age interval (x_i, x_{i+1}) after eliminating the number of person-years attributed to cause j ,
179 YLD_i and YLD_j is years lived with disability due to all-cause and specific-cause in the age
180 interval (x_i, x_{i+1}) , YLL_j is years of life lost due to specific-cause in the age interval (x_i, x_{i+1}) ,
181 and ω is the last age group in the life table.

182 The difference between $CEHALE_{[30-70]}$ and $HALE_{[30-70]}$ is the potential gain. We computed the
183 95% uncertainty intervals (UIs) by propagating the uncertainty from the GBD 2019 estimates.


184

185 **Results**

186 **Trends in age-standardized premature mortality for all NCDs and four major NCDs in** 187 **people aged 30-70, 1990-2030**

188 From 1990 to 2030, the age-standardized premature mortality of all NCDs showed varying
189 degrees of decline (ranging from 24.8% to 45.3%). Specifically, high- and upper-middle-

190 income countries had higher age-standardized premature mortality due to cancers in 1990 than
191 other countries, but the relative decline in this rate over three decades was more than 30 percent
192 (35.1%, 31.9%), higher than lower-middle- and low-income countries (4.5%, 9.9%). The
193 relative decline in age-standardized premature mortality from CVD was more than 50 percent
194 in high- and upper-middle-income countries (58.0%, 53.9%) and close to 30 percent in lower-
195 middle- and low-income countries (27.4%, 29.6%). The relative decline in age-standardized
196 premature mortality attributable to CRD was greatest in upper-middle-income countries (78.6%)
197 and smallest in high-income countries (35.1%), but the latter already had the lowest premature
198 mortality in 1990. Although the global age-standardized premature mortality for the above three
199 major NCDs decreased, the age-standardized premature mortality for diabetes mellitus
200 increased by 9.9%. The age-standardized premature mortality rate for diabetes in other
201 countries showed a downtrend, except for lower-middle-income countries. Age-standardized
202 premature mortality due to cancers is projected to remain higher in high- and upper-middle-
203 income countries until 2030 compared with lower-middle- and low-income countries, while
204 age-standardized premature mortality due to the three major NCDs are expected to be low
205 (figure 1).



206


207 **Fig.1 Trends in age-standardized premature mortality for all NCDs and four major NCDs**

208 **in people aged 30-70, 1990-2030**

209

210 **Changes in unconditional probability of premature death for four major NCDs in 2030**
211 **compared with 2015**

212 Figure 2 shows the estimated unconditional probability of premature death reduction
213 attributable to four major NCDs by 2030 compared to 2015. The global premature mortality in
214 2030 is only marginally lower than in 2015 and still far from the goal of reducing it by a third
215 (premature mortality: 0.024 in 2015, 0.023 in 2030; 0.016 in SDGs target 3.4). In 2030, the
216 unconditional probability of premature mortality for four major NCDs in most countries
217 remained at more than two-thirds of the 2015 baseline. While high-income countries will
218 struggle to reduce premature mortality by a third, their baseline for 2015 and projected for 2030
219 are well below global. For the other three income groups, lower income was associated with
220 higher premature mortality. The unconditional probability of premature death for four major
221 NCDs for 2015 and 2030 and their proportional changes with 95% UIs are provided in the
222 appendix (table S1).



223

224 **Fig.2 Changes in unconditional probability of premature death for four major NCDs in**

225 **2030 compared with 2015**

226 In the stack bar graph, gray and black columns are the unconditional probabilities of premature

227 mortality for the four major NCDs in 2015 and 2030, respectively. The red dots represent 2/3
228 of the unconditional probability of premature mortality at baseline in 2015. The red dotted lines,
229 blue dotted lines, and red solid lines represent the SDG target 3.4 reference value, the projected
230 value for 2030, and the baseline value for 2015 respectively.

231

232 **HALE_[30-70] and age-standardized YLDs for all NCDs and four major NCDs in people**
233 **aged 30-70, 2015**

234 In 2015, the HALE_[30-70] of the global population was 25.14 years of the 40-year lifespan that
235 corresponds to ages 30-70 years. The HALE_[30-70] in high- and upper-middle-income countries
236 (28.01 years, 25.71 years) were above the world level, while lower-middle- and low-income
237 countries (22.54 years, 21.35 years) were below it. The proportion of YLDs attributed to all
238 NCDs ranges from 88.2% in high-income countries to 75.1% in low-income countries. Overall,
239 the proportion of YLDs attributed to diabetes mellitus was the highest of the four major NCDs,
240 and the opposite was true for cancers. Cancers had a higher proportion of YLDs in high- and
241 upper-middle-income countries than in lower-middle- and low-income countries. Lower-
242 middle-income countries had the highest proportion of YLDs in CRD. Notably, upper-middle-
243 income countries had the lowest proportion of YLDs for CRD, but the leading cause of YLDs
244 was CVD. On the contrary, the proportion of YLDs in CVD in other countries was lower than
245 the world level (table 1). The average HALE and age-standardized YLDs between 30 years and
246 70 years with 95% UIs are provided in the appendix (table S2).

247 **Table 1 HALE_[30-70] and age-standardized YLDs for all NCDs and four major NCDs in**
248 **people aged 30-70, 2015**

	Global	High-income	Upper-middle-income	Lower-middle-income	Low-income
HALE _[30-70]	25.14	28.01	25.71	22.54	21.35
Attributable age-standardized YLDs (per 100 000)					
All-Cause	14087.2 (100%)	14646.2 (100%)	12940.2 (100%)	15091.9 (100%)	14839.6 (100%)
All NCDs	11808.2 (83.8%)	12916.1 (88.2%)	11169.6 (86.3%)	12113.3 (80.3%)	11140 (75.1%)
Major NCDs	1807.8 (12.8%)	1878.0 (12.9%)	1706.1 (13.2%)	1906.2 (12.6%)	1682.6 (11.3%)
Cancers	137.7 (1.0%)	244.4 (1.7%)	133.9 (1.0%)	73.9 (0.5%)	68.9 (0.5%)
CVD	511.3 (3.6%)	420.2 (2.9%)	563.6 (4.4%)	496.8 (3.3%)	520.6 (3.5%)
CRD	463.5 (3.3%)	508.5 (3.5%)	357.4 (2.8%)	576.6 (3.8%)	480 (3.2%)
Diabetes mellitus	695.3 (4.9%)	704.9 (4.8%)	651.2 (5.0%)	758.9 (5.0%)	613.1 (4.1%)


249 HALE_[30-70] = health adjusts life expectancy for people aged 30-70; YLDs = years lived with
 250 disability; NCDs = non-communicable diseases; CVD = cardiovascular diseases; CRD =
 251 chronic respiratory diseases

252

253 **Potential gains in health-adjusted life expectancy for people aged 30-70 in alternative**
 254 **future scenarios**

255 In all scenarios, the high-income group has the greatest potential gains in HALE_[30-70], above

256 the global average. For all specific causes, potential gains in $HALE_{[30-70]}$ decreases as income
 257 levels fall. In scenario A, the potential gains in $HALE_{[30-70]}$ of reducing premature mortality for
 258 four major NCDs are significantly lower than for all NCDs (range of difference for all income
 259 groups: 2.88 - 3.27 years). In scenario B and scenario C, the potential gains of $HALE_{[30-70]}$ in
 260 reducing premature mortality for all NCDs and the four major NCDs are very close (scenario
 261 B: 0.14 - 0.22, scenario C: 0.05 - 0.19). In scenarios A and B, the high-income group has the
 262 greatest potential gains in $HALE_{[30-70]}$ from cancer intervention, and the other income groups
 263 have the greatest potential gains in $HALE_{[30-70]}$ from cardiovascular diseases intervention. In
 264 scenario C, all income groups have the greatest potential gains in $HALE_{[30-70]}$ from diabetes
 265 and chronic respiratory diseases (figure 3).




266
 267 **Fig.3 For specific non-communicable diseases, potential gains in health-adjusted life**
 268 **expectancy for people aged 30-70 in alternative future scenarios**


269

270 For four major NCDs, reaching scenario A is estimated to yield fewer potential gains of
271 HALE_[30-70] in several Southern Africa and Middle Africa regions, including the Central African
272 Republic and Niger. The Pacific island states, including Fiji, Guam, Solomon Islands, and
273 Kiribati, in addition to the United States of America, have the larger benefits. Achieving
274 scenario B is estimated to yield higher potential gains of HALE_[30-70] in the United States of
275 America, Australia, Canada, Japan, Iceland, New Zealand, and Kuwait, but some African
276 regions, such as Lesotho and the Central African Republic, have lower potential gains of
277 HALE_[30-70]. In scenario C, HALE_[30-70] will show negative growth in some African and Pacific
278 island states, including Solomon Islands, Kiribati, Uzbekistan, Micronesia (Fed. States of),
279 Lesotho, and the Central African Republic. By contrast, HALE_[30-70] is still growing
280 aggressively in certain American, European, and Asian countries, such as Australia, Japan,
281 Iceland, United States of America, Canada, Switzerland, Luxembourg, Republic of Korea, New
282 Zealand, Kuwait, Italy, Norway, Singapore, Colombia, Puerto Rico, Spain, and France (figure
283 4). For all NCDs, four major NCDs, and the individual major NCDs, potential gains in
284 HALE_[30-70] with 95% UIs are provided in the appendix (table S3, table S4, and table S5).


Scenario A



Scenario B



Scenario C



285

286 **Fig.4 For four major non-communicable diseases, potential gains in health-adjusted life**

287 **expectancy for people aged 30-70 in alternative future scenarios**

288

289 **Discussion**

290 Our results highlight the significant gains in HALE_[30–70] worldwide on top of achieving SDGs
291 target 3.4, enabling survivors to rehabilitation from disability, which reflects the current high
292 premature mortality burden and disability burden of NCDs worldwide and the effect that efforts
293 to reduce it could have. However, based on trends in premature mortality over the past three
294 decades, we found that it seems impossible for most countries to reduce premature mortality
295 from four major NCDs to two-thirds of the 2015 baseline within the 10-year window. To our
296 knowledge, this is the first global study to assess the potential gains for HALE_[30–70] by reducing
297 premature death and disability as a whole and attaching equal importance to each. This study
298 highlights the limitations of the current framework from a visionary perspective and points
299 toward future directions for necessary global health policy with broadened scope. Our results
300 reinforce the urgency of meeting SDGs target 3.4 and highlight the importance of reducing
301 disability to improve quality of life.

302 We found HALE_[30–70] in high- and upper-middle-income countries were higher than that in
303 lower-middle- and low-income countries in 2015, but the gaps between high- and low-income
304 countries in age-standardized YLDs were small. Current demographic and health risk changes
305 have resulted in an increase in disability and an earlier onset of disability. The increase in the
306 number of total YLDs is significant in the context of population aging and health risk shifts^[29].
307 However, a horizontal comparison of HALE based on life expectancy between countries at
308 different economic levels does not reflect the lack of disability rehabilitation, as developed
309 countries have a higher life expectancy^[30]. The increase in the number of total YLDs may
310 burden economies and healthcare systems as the systems have not kept up with population

311 growth^[31]. Reducing premature mortality and disability requires enhancing primary care and
312 scale-up rehabilitation, driven by significant population aging and increased demand for long-
313 term care^[32-34]. Generally, Integrating rehabilitation into primary health care is limited in lower-
314 middle- and low-income countries, while high- and upper-middle-income countries do better<sup>[35-
315 37]</sup>. However, our results suggest that there is still a need for health policies in developed
316 countries to expand the coverage and willingness of rehabilitation and benefit more people.
317 Although 80% of NCDs occurred in lower-middle- and low-income countries^[7], we observed
318 that the potential gains in HALE₍₃₀₋₇₀₎ from reducing premature mortality and disability for the
319 four major NCDs are highest in high-income countries. The potential contributing factors may
320 be a decrease in poverty-related risk factors and an increase in behavioral risk factors, such as
321 tobacco consumption, harmful use of alcohol, and unhealthy diet^[9,38-41]. The four major NCDs
322 have received attention due to their high prevalence and high mortality rates. Excessive
323 premature mortality indicates early age of disease, rapid course of the disease, and poor
324 prognosis, and most of them are accompanied by severe complications. Surviving patients must
325 continue to live with the disease, develop new life routines, and adapt to the changes in health
326 status, which means they have a higher disability weight and more disability life years lost.
327 NCDs are long-term or lifelong, and a person cannot hold a temporary "patient role" and then
328 recover. In addition to socio-economic effects, exposure to products that are harmful to health
329 or unhealthy eating habits can also increase the risk of NCDs^[2,42,43]. NCDs can be controlled by
330 reducing the risk factors associated with these diseases, and guiding policy and priorities by
331 governments and other stakeholders are essential^[2]. It is recommended that lower-middle- and
332 low-income countries integrate rehabilitation into primary health care, while high- and upper-

333 middle-income countries focus on improving behavioral risk factors while ensuring that sound
334 rehabilitation and care benefit everyone.

335 Our results revealed estimates of what individual countries in four income groups might achieve
336 in controlling premature mortality in four major NCDs by 2030, which will provide
337 policymakers with experience from leading countries and evidence on health policy. Some
338 European countries are expected to do better in controlling NCDs' premature mortality, and
339 these countries are considered similar in terms of social structure and culture^[44]. The Nordic
340 welfare states have a long-standing commitment to egalitarian welfare policies that have helped
341 to achieve significant improvements in the health of covered all social groups^[44,45]. The WHO
342 European Region has mapped the lessons to the Consolidated Framework for Implementation
343 Research to support increasing coverage of quality essential health services in member states
344 with the lowest resources^[46]. In lower-middle- and low-income countries, priorities for the
345 prevention and control of NCDs compete with other important agendas such as poverty
346 eradication and environmental protection. It is encouraging that the UN and WHO are actively
347 working to combat the disease burden of NCDs in less developed regions and that NCDs-related
348 strategies such as Universal Health Coverage and Best Buy are integrated into primary health
349 care^[47]. But few countries met the recommended levels, and there is a lack of adequate
350 evaluation of many well-developed interventions^[48,49]. NCDs are killing and disabling people
351 at their peak productivity and are already another "poverty trap" on par with infectious
352 diseases^[50]. A substantial proportion of NCDs among adults could be prevented by early
353 screening and self-management, but lower-middle- and low-income countries appear to have
354 not fully adopted cost-effective strategies, possibly limited by the affordability and accessibility

355 of health care^[37,51].

356 This study has several strengths. First, we provided a trend analysis of regional and country-
357 level NCDs from a global health perspective and an intuitive assessment of progress towards
358 meeting SDGs target 3.4. Secondly, we expanded on SDGs target 3.4 of focusing on reducing
359 disability in survivors and reducing premature mortality, which is a key step toward reducing
360 the disease burden of NCDs. Third, the data sources for our study were estimates modeled from
361 the best available evidence and research, which be viewed as the best current estimate. Open
362 access databases of GBD across locations and the entire time series will be re-estimated by
363 relevant study collaborators each new cycle using the latest datasets and more advanced
364 modeling methods.

365 This study has at least two limitations. First, for individual NCDs, our analysis did not consider
366 causes beyond the four main NCDs. We limited our analysis to four major NCDs because they
367 are the leading cause of premature death, in line with the SDG target 3.4 emphasizes reducing
368 premature death. Further studies will take into account more NCDs with low mortality but a
369 higher disease burden for survivors. Second, in the hypothetical scenario of estimating potential
370 gains in HALE_[30-70], we converted YLLs to YLDs in equal proportions. For some causes and
371 their sequelae, current medical techniques may be difficult to relieve unbearable physical and
372 mental suffering while extending life. Disability weights and YLDs may be underestimated.
373 Therefore, our results are conservative estimates of potential gains of HALE_[30-70].

374 In conclusion, our findings show that meeting SDGs target 3.4 remains challenging for most
375 countries. Currently, the health life-year loss due to NCDs is highest in high-income countries.
376 The elimination of survivor disability from the SDG target 3.4 could lead to a sizable

377 improvement in average health-adjusts life expectancy lived for people aged 30 to70 years by
378 2030. We call on governments to make robust public health interventions and adequate
379 consideration of the independent or combined effects of health drivers, including health risk
380 factors, interventions, and broader sociodemographic and health system factors, to ensure that
381 health resources are properly distributed and available to all, especially to those most in need^[52].

382

383 **Acknowledgments**

384 The most important acknowledgment is to the GBD 2019 Diseases and Injuries Collaborators,
385 as well as to all the participants included in the study. The authors alone are responsible for the
386 views expressed in this article and they do not necessarily represent the views, decisions, or
387 policies of the institutions with which they are affiliated.

388 **Competing interests**

389 No competing interests were declared.

390 **Author contributions**

391 Jun-Yan Xi: Conceptualization; Data curation; Software; Formal analysis; Investigation;
392 Visualization; Methodology; Writing - original draft. Wang-Jian Zhang: Formal analysis;
393 Validation; Writing - review and editing. Zhuo Chen: Formal analysis; Validation; Writing -
394 review and editing. Yan-Ting Zhang: Investigation; Visualization; Methodology. Li-Chang
395 Chen: Investigation; Visualization; Methodology. Yu-Qin Zhang: Investigation; Visualization;
396 Methodology. Xiao Lin: Conceptualization; Resources; Supervision; Funding acquisition;
397 Methodology; Project administration; Writing - review and editing. Yuan-Tao Hao:
398 Conceptualization; Resources; Supervision; Funding acquisition; Methodology; Project

399 administration; Writing – review and editing.

400 **Data availability statement**

401 The full dataset in this study can be obtained from the Institute for Health Metrics and
402 Evaluation (<https://www.healthdata.org/>) and World Population Prospects 2019
403 (<https://population.un.org/wpp/>). All data generated during this study are included in the
404 manuscript and supporting files.

405 **Ethics**

406 The requirement for ethical board approval was waived because this study is secondary data
407 analysis. All data were aggregated and did not contain any information at the individual
408 levels. Therefore, there were no specific ethical issues warranted special attention.

409

410

References

- 411 1. World Health Statistics. World Health Statistics 2021.
412 <https://apps.who.int/iris/bitstream/handle/10665/342703/9789240027053-eng.pdf>. accessed
413 December 1, 2021
- 414 2. World Health Organization. Noncommunicable diseases. [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)
415 [room/fact-sheets/detail/noncommunicable-diseases](https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases). accessed December 1, 2021
- 416 3. United Nations. Transforming our World: The 2030 Agenda for Sustainable Development.
417 <https://sustainabledevelopment.un.org/post2015/transformingourworld/publication>. accessed
418 December 1, 2021
- 419 4. NCD Countdown Collaborators. NCD Countdown 2030. <https://ncdcountdown.org/>.
420 accessed December 1, 2021
- 421 5. Bennett JE, Stevens GA, Mathers CD, et al. NCD Countdown 2030: worldwide trends in
422 non-communicable disease mortality and progress towards Sustainable Development Goal
423 target 3.4. *The Lancet*. 2018; 392: 1072-88.
- 424 6. Nugent R, Bertram MY, Jan S, et al. Investing in non-communicable disease prevention
425 and management to advance the Sustainable Development Goals. *The Lancet*. 2018; 391: 2029-
426 35.
- 427 7. Niessen LW, Mohan D, Akuoku JK, et al. Tackling socioeconomic inequalities and non-
428 communicable diseases in low-income and middle-income countries under the Sustainable
429 Development agenda. *The Lancet*. 2018; 391: 2036-46.
- 430 8. Magnusson RS. Framework legislation for non-communicable diseases: and for the
431 Sustainable Development Goals? *BMJ Global Health*. 2017; 2: e385.

- 432 9. Cao B, Bray F, Ilbawi A, et al. Effect on longevity of one-third reduction in premature
433 mortality from non-communicable diseases by 2030: a global analysis of the Sustainable
434 Development Goal health target. *The Lancet Global Health*. 2018; 6: e1288-96.
- 435 10. Martinez R, Lloyd-Sherlock P, Soliz P, et al. Trends in premature avertable mortality from
436 non-communicable diseases for 195 countries and territories, 1990 – 2017: a population-based
437 study. *The Lancet Global Health*. 2020; 8: e511-23.
- 438 11. Zhou T, Guan H, Yao J, et al. The quality of life in Chinese population with chronic non-
439 communicable diseases according to EQ-5D-3L: a systematic review. *QUAL LIFE RES*. 2018;
440 27: 2799-814.
- 441 12. Van Wilder L, Clays E, Devleeschauwer B, et al. Health-related quality of life in patients
442 with non-communicable disease: study protocol of a cross-sectional survey. *BMJ OPEN*. 2020;
443 10: e37131.
- 444 13. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204
445 countries and territories, 1990 – 2019: a systematic analysis for the Global Burden of Disease
446 Study 2019. *The Lancet*. 2020; 396: 1204-22.
- 447 14. Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific fertility, mortality,
448 healthy life expectancy (HALE), and population estimates in 204 countries and territories,
449 1950 – 2019: a comprehensive demographic analysis for the Global Burden of Disease Study
450 2019. *The Lancet*. 2020; 396: 1160-203.
- 451 15. Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries
452 and territories, 1990 – 2019: a systematic analysis for the Global Burden of Disease Study 2019.
453 *The Lancet*. 2020; 396: 1223-49.

- 454 16. University of Washington, Institute for Health Metrics and Evaluation. Global Burden of
455 Disease (GBD 2019). <http://www.healthdata.org/gbd/2019>. accessed December 1, 2021
- 456 17. Ševčíková H, Raftery AE. bayesPop: Probabilistic Population Projections. J STAT
457 SOFTW. 2016; 75.
- 458 18. Raftery AE, Alkema L, Gerland P. Bayesian Population Projections for the United Nations.
459 STAT SCI. 2014; 29: 58-68.
- 460 19. United Nations, Department of Economic and Social Affairs, Population Division.
461 Probabilistic Population Projections Rev. 1 based on the World Population Prospects 2019.
462 <https://population.un.org/wpp/Download/Probabilistic/Population/>. accessed December 1,
463 2021
- 464 20. World Bank. World Bank Country and Lending Groups.
465 [https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
466 [lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups). accessed December 1, 2021
- 467 21. Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health
468 Estimates Reporting: the GATHER statement. The Lancet. 2016; 388: e19-23.
- 469 22. Riebler A. BAPC: Projection of cancer incidence and mortality data using Bayesian APC
470 models fitted with INLA. <https://rdrr.io/rforge/BAPC/>. accessed December 1, 2021
- 471 23. Riebler A, Held L. Projecting the future burden of cancer: Bayesian age-period-cohort
472 analysis with integrated nested Laplace approximations. BIOMETRICAL J. 2017; 59: 531-49.
- 473 24. Schmid VJ, Held L. Bayesian Age-Period-Cohort Modeling and Prediction -BAMP. J
474 STAT SOFTW. 2007; 21.
- 475 25. Tsai SP, Lee ES, Hardy RJ. The effect of a reduction in leading causes of death: potential

- 476 gains in life expectancy. American journal of public health (1971). 1978; 68: 966-71.
- 477 26. Eayres D, Williams ES. Evaluation of methodologies for small area life expectancy
478 estimation. Journal of epidemiology and community health (1979). 2004; 58: 243-49.
- 479 27. Hu X, Sun X, Li Y, et al. Potential gains in health-adjusted life expectancy from reducing
480 four main non-communicable diseases among Chinese elderly. BMC GERIATR. 2019; 19: 16.
- 481 28. Wang GD, Lai DJ, Burau KD, et al. Potential gains in life expectancy from reducing heart
482 disease, cancer, Alzheimer's disease, kidney disease or HIV/AIDS as major causes of death in
483 the USA. PUBLIC HEALTH. 2013; 127: 348-56.
- 484 29. Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based
485 on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of
486 Disease Study 2019. The Lancet. 2020; 396: 2006-17.
- 487 30. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-
488 cause mortality, and cause-specific mortality for 249 causes of death, 1980 - 2015: a systematic
489 analysis for the Global Burden of Disease Study 2015. The Lancet. 2016; 388: 1459-544.
- 490 31. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence,
491 and years lived with disability for 354 diseases and injuries for 195 countries and territories,
492 1990 - 2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet.
493 2018; 392: 1789-858.
- 494 32. Anton SD, Woods AJ, Ashizawa T, et al. Successful aging: Advancing the science of
495 physical independence in older adults. AGEING RES REV. 2015; 24: 304-27.
- 496 33. Crocker T, Forster A, Young J, et al. Physical rehabilitation for older people in long-term
497 care. COCHRANE DB SYST REV. 2013: D4294.

- 498 34. Forster A, Lambley R, Young JB. Is physical rehabilitation for older people in long-term
499 care effective? Findings from a systematic review. *AGE AGEING*. 2010; 39: 169-75.
- 500 35. Abreu A, Pesah E, Supervia M, et al. Cardiac rehabilitation availability and delivery in
501 Europe: How does it differ by region and compare with other high-income countries? *EUR J*
502 *PREV CARDIOL*. 2019; 26: 1131-46.
- 503 36. Thornicroft G, Ahuja S, Barber S, et al. Integrated care for people with long-term mental
504 and physical health conditions in low-income and middle-income countries. *The Lancet*
505 *Psychiatry*. 2019; 6: 174-86.
- 506 37. Hearn J, Ssinabulya I, Schwartz JI, et al. Self-management of non-communicable diseases
507 in low- and middle-income countries: A scoping review. *PLOS ONE*. 2019; 14: e219141.
- 508 38. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and
509 mortality in 155 722 individuals from 21 high-income, middle-income, and low-income
510 countries (PURE): a prospective cohort study. *The Lancet*. 2020; 395: 795-808.
- 511 39. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and
512 deaths attributable to potentially modifiable risk factors in the United States. *CA: A Cancer*
513 *Journal for Clinicians*. 2018; 68: 31-54.
- 514 40. Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-Month Alcohol Use, High-Risk
515 Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013.
516 *JAMA PSYCHIAT*. 2017; 74: 911.
- 517 41. Cena H, Calder PC. Defining a Healthy Diet: Evidence for the Role of Contemporary
518 Dietary Patterns in Health and Disease. *NUTRIENTS*. 2020; 12: 334.
- 519 42. Afshin A, Sur PJ, Fay KA, et al. Health effects of dietary risks in 195 countries, 1990 –

- 520 2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet*. 2019;
521 393: 1958-72.
- 522 43. Licher S, Heshmatollah A, van der Willik KD, et al. Lifetime risk and multimorbidity of
523 non-communicable diseases and disease-free life expectancy in the general population: A
524 population-based cohort study. *PLOS MED*. 2019; 16: e1002741.
- 525 44. Balaj M, Huijts T, McNamara CL, et al. Non-communicable diseases and the social
526 determinants of health in the Nordic countries: Findings from the European Social Survey
527 (2014) special module on the social determinants of health. *SCAND J PUBLIC HEALT*. 2017;
528 45: 90-102.
- 529 45. Thomson KH, Renneberg A, McNamara CL, et al. Regional inequalities in self-reported
530 conditions and non-communicable diseases in European countries: Findings from the European
531 Social Survey (2014) special module on the social determinants of health. *EUR J PUBLIC*
532 *HEALTH*. 2017; 27: 14-21.
- 533 46. Collins D, Laatikainen T, Farrington J. Implementing essential interventions for
534 cardiovascular disease risk management in primary healthcare: lessons from Eastern Europe
535 and Central Asia. *BMJ Global Health*. 2020; 5: e2111.
- 536 47. Ganju A, Goulart AC, Ray A, et al. Systemic Solutions for Addressing Non-
537 Communicable Diseases in Low- and Middle-Income Countries. *Journal of multidisciplinary*
538 *healthcare*. 2020; Volume 13: 693-707.
- 539 48. Tesema AG, Ajisehiri WS, Abimbola S, et al. How well are non-communicable disease
540 services being integrated into primary health care in Africa: A review of progress against World
541 Health Organization's African regional targets. *PLOS ONE*. 2020; 15: e240984.

- 542 49. Allen LN, Pullar J, Wickramasinghe KK, et al. Evaluation of research on interventions
543 aligned to WHO ‘Best Buys’ for NCDs in low-income and lower-middle-income countries:
544 a systematic review from 1990 to 2015. *BMJ Global Health*. 2018; 3: e535.
- 545 50. STUCKLER D. Population Causes and Consequences of Leading Chronic Diseases: A
546 Comparative Analysis of Prevailing Explanations. *The Milbank Quarterly*. 2008; 86: 273-326.
- 547 51. Fidler MM, Gupta S, Soerjomataram I, et al. Cancer incidence and mortality among young
548 adults aged 20 – 39 years worldwide in 2012: a population-based study. *The Lancet Oncology*.
549 2017; 18: 1579-89.
- 550 52. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost,
551 and all-cause and cause-specific mortality for 250 causes of death: reference and alternative
552 scenarios for 2016 – 40 for 195 countries and territories. *The Lancet*. 2018; 392: 2052-90.